Retatrutide represents the next evolution in metabolic treatment, offering what scientists describe as a triple-action approach that could potentially deliver even more impressive results than current medications
GLP-1 plays many roles in the body that affect appetite and blood sugar control
Heres what early studies have shown: Pancreatitis: Reported in about 0.4% Gallbladder problems: Seen in about 1.1% , with no cases in the placebo group Heart rhythm changes: Reported more often with retatrutide ( about 6% vs 3% with placebo ) Liver enzyme increases: Rare (around 1% ), with overall liver health markers staying stable While these serious side effects were uncommon, theyre still important to keep in mind
Despite the above preclinical evidence, there is no significant effect on appetite, energy intake or energy expenditure following a GIP acute infusion over a short period
[DOI] [PubMed] [Google Scholar] 87.Noseda R., Burstein R
HRQoL was assessed with the Pediatric Quality of Life Inventory (PedsQL)